Opinion

Video

Case 1: A 68-Year-Old Man with Bone-Predominant Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Author(s):

Jose De La Cerda III, MD, MPH

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      Related Videos
      Addressing Remaining Unmet Needs in mCRPC
      Addressing Remaining Unmet Needs in mCRPC
      Use and Sequencing of Novel Treatments in NMIBC
      Use and Sequencing of Novel Treatments in NMIBC
      The DORA Trial
      The DORA Trial
      FDA-Approved Treatments for BCG-Unresponsive NMIBC
      FDA-Approved Treatments for BCG-Unresponsive NMIBC
      Cretostimogene Grenadenorepvec and Integration of Novel Therapies in High-Risk BCG-Unresponsive NMIBC
      Cretostimogene Grenadenorepvec and Integration of Novel Therapies in High-Risk BCG-Unresponsive NMIBC
      Clinical Perspectives on Early Use of RAD-ENZ
      Clinical Perspectives on Early Use of RAD-ENZ
      Treatment Selection for mCRPC
      Treatment Selection for mCRPC
      Other Investigational Drug Delivery Systems in NMIBC
      Other Investigational Drug Delivery Systems in NMIBC
      Medcast series
      Episode 3 Video: Managing Overactive Bladder: From Dual Diagnoses to Geriatric Challenges
      The Future of RAD-ENZ Combination Therapy
      The Future of RAD-ENZ Combination Therapy
      Related Content
      © 2025 MJH Life Sciences

      All rights reserved.